HK1106700A1 - Use of botulinum toxin for the manufacture of a medicament for reducing low back pain - Google Patents

Use of botulinum toxin for the manufacture of a medicament for reducing low back pain

Info

Publication number
HK1106700A1
HK1106700A1 HK07112425A HK07112425A HK1106700A1 HK 1106700 A1 HK1106700 A1 HK 1106700A1 HK 07112425 A HK07112425 A HK 07112425A HK 07112425 A HK07112425 A HK 07112425A HK 1106700 A1 HK1106700 A1 HK 1106700A1
Authority
HK
Hong Kong
Prior art keywords
medicament
manufacture
botulinum toxin
back pain
low back
Prior art date
Application number
HK07112425A
Other languages
English (en)
Inventor
Roger K Aoki
Michael W Grayston
Steven R Carlson
Judith M Leon
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22634387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1106700(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of HK1106700A1 publication Critical patent/HK1106700A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/06Anti-spasmodics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK07112425A 1993-12-28 2007-11-14 Use of botulinum toxin for the manufacture of a medicament for reducing low back pain HK1106700A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17399693A 1993-12-28 1993-12-28

Publications (1)

Publication Number Publication Date
HK1106700A1 true HK1106700A1 (en) 2008-03-20

Family

ID=22634387

Family Applications (6)

Application Number Title Priority Date Filing Date
HK01103981A HK1033274A1 (en) 1993-12-28 2001-06-11 Botulinum toxins for treating dystonia
HK04107484.4A HK1064599A1 (en) 1993-12-28 2004-09-28 Use of botulinum toxins against sweating in humans
HK05103646A HK1070831A1 (en) 1993-12-28 2005-04-28 Neurotoxic component of botulinum toxins for treating cervical dystonia
HK05103928A HK1071071A1 (en) 1993-12-28 2005-05-10 Neurotoxic component of botulinum toxin for modulating cholinergic controlled secretions
HK05105116.3A HK1072375A1 (en) 1993-12-28 2005-06-20 Use of the neurotoxic component of botulinum toxin for treating smooth muscle disorders
HK07112425A HK1106700A1 (en) 1993-12-28 2007-11-14 Use of botulinum toxin for the manufacture of a medicament for reducing low back pain

Family Applications Before (5)

Application Number Title Priority Date Filing Date
HK01103981A HK1033274A1 (en) 1993-12-28 2001-06-11 Botulinum toxins for treating dystonia
HK04107484.4A HK1064599A1 (en) 1993-12-28 2004-09-28 Use of botulinum toxins against sweating in humans
HK05103646A HK1070831A1 (en) 1993-12-28 2005-04-28 Neurotoxic component of botulinum toxins for treating cervical dystonia
HK05103928A HK1071071A1 (en) 1993-12-28 2005-05-10 Neurotoxic component of botulinum toxin for modulating cholinergic controlled secretions
HK05105116.3A HK1072375A1 (en) 1993-12-28 2005-06-20 Use of the neurotoxic component of botulinum toxin for treating smooth muscle disorders

Country Status (9)

Country Link
EP (23) EP0737074B1 (xx)
JP (33) JP3238154B2 (xx)
AU (1) AU688452B2 (xx)
CA (2) CA2180011C (xx)
DE (23) DE69427869T2 (xx)
ES (18) ES2237033T5 (xx)
FR (1) FR08C0034I1 (xx)
HK (6) HK1033274A1 (xx)
WO (1) WO1995017904A2 (xx)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
DE69435254D1 (de) 1993-06-10 2009-12-31 Allergan Inc Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
EP0737074B1 (en) * 1993-12-28 2001-08-01 Allergan Sales, Inc. Botulinum toxins for treating hyperhydrosis
US8187612B2 (en) 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
AU2007202480B2 (en) * 1993-12-28 2009-01-29 Allergan, Inc. Method for treating pain associated with a muscle disorder
US8557256B2 (en) 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
DK0758900T3 (da) * 1994-05-09 2002-07-29 William J Binder Botulinumtoksin til reduktion af migræne-hovedpinesmerter
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6699966B1 (en) 1996-07-08 2004-03-02 University Of Massachusetts Proteins within the type E botulinum neurotoxin complex
US6780413B2 (en) 1996-09-19 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin (mAB-RICIN) for the treatment of focal movement disorders
US7449192B2 (en) 1997-07-15 2008-11-11 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
US7470431B2 (en) 1997-07-15 2008-12-30 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer
US7455845B2 (en) 1997-07-15 2008-11-25 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
AU2008201535C1 (en) * 1997-07-15 2013-09-12 Allergan, Inc. Use of neurotoxin therapy for treatment of urologic and related disorders
US9066943B2 (en) 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
PT1011695E (pt) * 1997-07-15 2006-07-31 Univ Colorado Utilizacao de terapia com neurotoxina para tratamento de doencas da prostata
AU2006225233C1 (en) * 1997-07-15 2011-02-10 Allergan, Inc. Use of neurotoxin therapy for treatment of urologic and related disorders
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
JP2002501033A (ja) 1998-01-26 2002-01-15 ユニバーシティー オブ マサチューセッツ A型ボツリヌス菌の生物学的活性赤血球凝集素とその使用法
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
US8790897B2 (en) 1998-08-25 2014-07-29 Syntaxin Ltd. Treatment of mucus hypersecretion
GB9818548D0 (en) * 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19856897A1 (de) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6767544B2 (en) * 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US6977080B1 (en) * 1999-08-10 2005-12-20 Allergan, Inc. Intrapericardial botulinum toxin treatment for bradycardia
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6261572B1 (en) 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6358513B1 (en) * 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6328977B1 (en) * 2000-02-22 2001-12-11 Allergan Sales, Inc. Method for treating hyperparathyroidism
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6565870B1 (en) * 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
WO2002009743A1 (en) * 2000-08-02 2002-02-07 Allergan Sales, Inc. Method for treating a neoplasm
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6827931B1 (en) * 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
ITUD20010002A1 (it) 2001-01-05 2002-07-05 Univ Degli Studi Udine Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo
GB0111146D0 (en) * 2001-05-04 2001-06-27 Imp College Innovations Ltd Methods
JP2003009897A (ja) 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
KR20030018827A (ko) * 2001-08-31 2003-03-06 서구일 A형 보툴리눔 독소를 유효성분으로 포함하는 신경차단제,및 이를 이용한 교감신경절 차단의 적응질환 치료제
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US7255866B2 (en) 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US20030113349A1 (en) 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US6776991B2 (en) 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
EP1551430A2 (en) * 2002-10-15 2005-07-13 Allergan, Inc. Botulinum toxin dental therapies and procedures
US20040086532A1 (en) 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
US7238357B2 (en) 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
MXPA05009424A (es) 2003-03-06 2006-02-10 Botulinum Toxin Res Ass Inc Tratamiento de chalazion cronico y hordeolum con la toxina botulinica.
JP2007528352A (ja) * 2003-03-06 2007-10-11 ボツリヌム・トクシン・リサーチ・アソシエイツ・インコーポレイテッド 洞炎に関連する慢性の顔面痛および頭痛のボツリヌス毒素での治療
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
FR2857595B1 (fr) * 2003-07-18 2005-10-07 Sod Conseils Rech Applic Utilisation de toxine botulique pour preparer un medicament destine a prevenir ou traiter les troubles sonores lies a l'agonie
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
DE602005001854T2 (de) * 2004-02-12 2008-04-17 Philip San Clemente Radovic Behandlung von abweichungen der ersten metatarsophalangealen verbindung des fusses
US7276244B2 (en) 2004-02-12 2007-10-02 Philip Radovic Methods of treating abnormalities of the first metatarsophalangeal joint of the foot
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
LT2985039T (lt) * 2004-03-03 2018-11-12 Revance Therapeutics, Inc. Botulino toksinų vietinis taikymas ir jų įvedimas per odą
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
WO2005120546A2 (en) 2004-03-03 2005-12-22 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
JP2008531732A (ja) 2005-03-03 2008-08-14 ルバンス セラピュティックス インク. ボツリヌス毒素の局所塗布及び経皮送達のための組成物及び方法
EP1747782A1 (en) 2005-07-19 2007-01-31 Cesare Montecucco Products for topical application comprising lysophospholipids and fatty acids
US7910116B2 (en) 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
WO2007059528A2 (en) 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
US7655625B2 (en) 2006-02-13 2010-02-02 Allergan, Inc. Methods of treating blepharospasm using cyclosporine components
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US7811586B2 (en) 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
FR2907680B1 (fr) * 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
US8002717B2 (en) 2007-03-30 2011-08-23 Anders Fagergren Quantification of mechanical and neural contributions to spasticity
HUE031136T2 (en) 2007-07-26 2017-07-28 Revance Therapeutics Inc Antimicrobial peptide and preparations
EP2072039A1 (en) * 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
US8470337B2 (en) 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
US20100124559A1 (en) * 2008-11-20 2010-05-20 Allergan, Inc. Early Treatment and Prevention of Increased Muscle Tonicity
PL2379104T3 (pl) 2008-12-31 2018-07-31 Revance Therapeutics, Inc. Preparaty toksyny botulinowej do wstrzykiwania
BRPI1015938A2 (pt) 2009-06-25 2016-09-27 Revance Therapeutics Inc formulações da toxina botulínica livre de albumina
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
MX370929B (es) 2012-10-28 2020-01-08 Revance Therapeutics Inc Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
RU2545453C2 (ru) * 2013-03-21 2015-03-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения переломов нижней челюсти
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
WO2016002984A1 (ko) * 2014-06-30 2016-01-07 (주)메디톡스 보툴리눔 독소를 유효성분으로 포함하는 골관절염 치료용 약제학적 조성물 및 그를 이용한 골관절염 치료 방법
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11191819B2 (en) * 2018-08-28 2021-12-07 Ira Sanders Skin therapeutics
RU2732204C1 (ru) * 2020-01-28 2020-09-14 Частное учреждение образовательная организация высшего образования "Медицинский университет "Реавиз" Способ лечения головных болей напряжения по Гурову-Левину
CA3194375A1 (en) * 2020-10-07 2022-04-14 Hak Kun Kim Vacuum drying method for botulinum toxin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362731A (en) * 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4664911A (en) 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US5053005A (en) 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
GB9022250D0 (en) * 1990-10-12 1990-11-28 Glaxo Group Ltd Medicaments
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
WO1994000481A1 (en) * 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
EP0679090A1 (en) * 1993-01-15 1995-11-02 Interactive Biologics Associates Method for treating myofascial pain syndrome
CA2164626C (en) * 1993-06-10 2004-11-23 K. Roger Aoki Multiple botulinum toxins for treating neuromuscular disorders and conditions
DE69435254D1 (de) * 1993-06-10 2009-12-31 Allergan Inc Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
EP0737074B1 (en) * 1993-12-28 2001-08-01 Allergan Sales, Inc. Botulinum toxins for treating hyperhydrosis
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
DK0758900T3 (da) * 1994-05-09 2002-07-29 William J Binder Botulinumtoksin til reduktion af migræne-hovedpinesmerter
JP2001104991A (ja) * 1999-10-12 2001-04-17 Toyoaki Kubota 循環水の有機質除去剤

Also Published As

Publication number Publication date
EP1010431A3 (en) 2001-05-16
EP1005867A2 (en) 2000-06-07
JP2008056682A (ja) 2008-03-13
ES2340172T3 (es) 2010-05-31
DE69434610T2 (de) 2008-11-27
EP1591129A3 (en) 2005-11-16
DE69427869T2 (de) 2002-04-11
JP2008063339A (ja) 2008-03-21
JP2002104990A (ja) 2002-04-10
ES2207910T5 (es) 2010-05-21
ES2355491T3 (es) 2011-03-28
DE69435149D1 (de) 2008-11-20
JP2002087987A (ja) 2002-03-27
EP1488803A1 (en) 2004-12-22
JP2006160754A (ja) 2006-06-22
DE69434511D1 (de) 2006-03-02
CA2682117A1 (en) 1995-07-06
JP2002097156A (ja) 2002-04-02
DE69435302D1 (de) 2010-08-26
EP1477183A1 (en) 2004-11-17
EP1147776A2 (en) 2001-10-24
HK1033274A1 (en) 2001-08-24
HK1072375A1 (en) 2005-08-26
HK1071071A1 (en) 2005-07-08
EP1477183B1 (en) 2005-11-02
JP2008037877A (ja) 2008-02-21
EP1598077A1 (en) 2005-11-23
JP3238154B2 (ja) 2001-12-10
DE122008000042I1 (de) 2009-01-02
DE69434008T2 (de) 2005-09-22
JP2007262086A (ja) 2007-10-11
EP1488803B1 (en) 2008-03-26
JP2002068989A (ja) 2002-03-08
ES2163090T3 (es) 2002-01-16
EP1600163A1 (en) 2005-11-30
EP1147775A3 (en) 2003-01-15
DE69435330D1 (de) 2011-01-27
EP1147776B1 (en) 2010-12-15
ES2248780T3 (es) 2008-06-16
JP2012167115A (ja) 2012-09-06
EP1600163B1 (en) 2010-02-17
ES2237033T5 (es) 2010-10-29
EP1598077B1 (en) 2009-11-04
EP1147775A2 (en) 2001-10-24
DE69428813T2 (de) 2002-04-04
JP2002097145A (ja) 2002-04-02
EP1010431A2 (en) 2000-06-21
DE69435194D1 (de) 2009-04-16
JP2006160753A (ja) 2006-06-22
DE69435270D1 (de) 2010-04-01
ES2159624T3 (es) 2001-10-16
EP1366770A3 (en) 2004-03-17
EP1591129B1 (en) 2010-02-24
DE122008000043I1 (de) 2008-11-20
EP1147775B1 (en) 2009-03-04
EP1147776A3 (en) 2003-01-15
ES2309973T3 (es) 2008-12-16
JP2010209105A (ja) 2010-09-24
EP0737074A1 (en) 1996-10-16
AU1516295A (en) 1995-07-17
DE69435249D1 (de) 2009-12-17
HK1064599A1 (en) 2005-02-04
ES2251651T3 (es) 2008-07-16
EP0737074B1 (en) 2001-08-01
EP1010431B1 (en) 2005-03-30
EP1103267B1 (en) 2004-09-15
DE69434319T2 (de) 2006-03-09
JP2008056683A (ja) 2008-03-13
DE69427869D1 (de) 2001-09-06
DE69434535D1 (de) 2005-12-08
DE69434511T2 (de) 2006-07-13
DE69435116D1 (de) 2008-08-21
DE69435276D1 (de) 2010-04-08
EP1005867B2 (en) 2010-02-17
EP1563843B1 (en) 2013-08-07
EP1602379A1 (en) 2005-12-07
DE69434008D1 (de) 2004-10-21
ES2339865T3 (es) 2010-05-26
DE69434443T2 (de) 2006-05-24
EP1421948A3 (en) 2004-06-16
EP1366771A2 (en) 2003-12-03
EP1072270A3 (en) 2002-08-07
DE69434319T3 (de) 2011-02-17
JP2010202660A (ja) 2010-09-16
EP1072270B1 (en) 2005-10-19
DE122009000038I1 (de) 2009-11-05
EP0770395B1 (en) 2001-10-24
WO1995017904A3 (en) 1995-10-19
DE69434540T2 (de) 2009-06-18
AU688452B2 (en) 1998-03-12
DE69433394D1 (de) 2004-01-15
JP2010202661A (ja) 2010-09-16
EP1421948B1 (en) 2008-10-08
ES2246800T3 (es) 2006-03-01
EP0770395A1 (en) 1997-05-02
JP2008031176A (ja) 2008-02-14
DE69435243D1 (de) 2009-11-19
JP2002087986A (ja) 2002-03-27
JP2012167116A (ja) 2012-09-06
CA2180011C (en) 2001-05-15
HK1070831A1 (en) 2005-06-30
EP1591129A2 (en) 2005-11-02
EP1072270A2 (en) 2001-01-31
JP2013006865A (ja) 2013-01-10
JP2012167114A (ja) 2012-09-06
EP1010431B2 (en) 2010-07-14
DE69433394T2 (de) 2004-10-14
ES2347384T3 (es) 2010-10-28
JP2010202659A (ja) 2010-09-16
JP2002087984A (ja) 2002-03-27
EP1366770B1 (en) 2005-07-27
EP1502600A1 (en) 2005-02-02
EP2027872A1 (en) 2009-02-25
DE69435321D1 (de) 2010-12-16
FR08C0034I1 (fr) 2008-09-26
DE69434319D1 (de) 2005-05-04
ES2207910T3 (es) 2004-06-01
ES2247575T3 (es) 2006-03-01
JP2002087985A (ja) 2002-03-27
JP2012188433A (ja) 2012-10-04
DE69433394T3 (de) 2010-08-12
DE69428813D1 (de) 2001-11-29
JP2002087988A (ja) 2002-03-27
DE69434535T2 (de) 2006-07-20
ES2319860T3 (es) 2009-05-14
JP2012167117A (ja) 2012-09-06
EP1486214A1 (en) 2004-12-15
EP1563843A1 (en) 2005-08-17
EP1366771A3 (en) 2003-12-10
JP2012197287A (ja) 2012-10-18
DE69434610D1 (de) 2008-08-21
EP1757325B1 (en) 2010-11-03
EP1005867A3 (en) 2001-06-13
EP1421948A2 (en) 2004-05-26
EP1790352A1 (en) 2007-05-30
JPH09507234A (ja) 1997-07-22
EP1366770A2 (en) 2003-12-03
WO1995017904A2 (en) 1995-07-06
ES2237033T3 (es) 2005-07-16
CA2180011A1 (en) 1995-07-06
ES2332905T3 (es) 2010-02-15
JP2002104991A (ja) 2002-04-10
EP2027872B1 (en) 2010-07-14
ES2223393T3 (es) 2005-03-01
JP2002114706A (ja) 2002-04-16
DE69434443D1 (de) 2005-09-01
ES2242126T3 (es) 2005-11-01
EP1757325A1 (en) 2007-02-28
EP1502600B1 (en) 2009-10-07
DE69434540D1 (de) 2009-03-26
EP1790352B1 (en) 2008-07-09
EP1103267A1 (en) 2001-05-30
JP2006160756A (ja) 2006-06-22
EP1005867B1 (en) 2003-12-03
EP1366771B1 (en) 2008-03-26
ES2334357T3 (es) 2010-03-09
JP2006160755A (ja) 2006-06-22

Similar Documents

Publication Publication Date Title
HK1106700A1 (en) Use of botulinum toxin for the manufacture of a medicament for reducing low back pain
HU9402473D0 (en) Medical valve
IL108755A0 (en) Catheter
GB9314640D0 (en) Tunnellimg catheter
SG46610A1 (en) Syringe
CZ123096A3 (en) Syringe
GB2279879B (en) Medicament inhalers
GB9317539D0 (en) Catheter
GB9303538D0 (en) Medicament presentation
ZA941163B (en) Medicament presentation
AU5658094A (en) Use of potassium channel activators for the manufacture of a medicament for the treatment of pain
GB2284158B (en) Catheter
GB9319772D0 (en) Therapeutic agent
ZA946217B (en) Therapeutic combination
GB2284554B (en) Syringe
BG98997A (en) Syringe
IL109993A0 (en) Ipsapirone medicament formulation
GB9321098D0 (en) Catheter
GB9305242D0 (en) Therapeutic alcohols
GB9322063D0 (en) Medical syringe
EG20066A (en) Syringe
GB9214905D0 (en) Medicament
GB9204767D0 (en) Medicament
GB9315401D0 (en) Intravenous catheter
GB9306646D0 (en) Therapeutic agetns

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20141215